TriSalus Life Sciences Inc [TLSI] stock is trading at $4.9, down -0.41%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The TLSI shares have gain 10.61% over the last week, with a monthly amount drifted -4.30%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Cantor Fitzgerald started tracking the stock with Overweight rating on December 17, 2024, and set its price target to $10. On November 11, 2024, ROTH MKM initiated with a Buy rating and assigned a price target of $11 on the stock. Northland Capital started tracking the stock assigning a Outperform rating and suggested a price target of $12.50 on October 25, 2024. Oppenheimer initiated its recommendation with a Outperform and recommended $10 as its price target on September 16, 2024. Canaccord Genuity started tracking with a Buy rating for this stock on May 30, 2024, and assigned it a price target of $12.
TriSalus Life Sciences Inc [TLSI] stock has fluctuated between $3.42 and $5.88 over the past year. Currently, Wall Street analysts expect the stock to reach $10.5 within the next 12 months. TriSalus Life Sciences Inc [NASDAQ: TLSI] shares were valued at $4.9 at the most recent close of the market. An investor can expect a potential return of 114.29% based on the average TLSI price forecast.
Analyzing the TLSI fundamentals
TriSalus Life Sciences Inc [NASDAQ:TLSI] reported sales of 35.99M for the trailing twelve months, which represents a growth of 52.27%. Gross Profit Margin for this corporation currently stands at 0.85% with Operating Profit Margin at -0.86%, Pretax Profit Margin comes in at -0.87%, and Net Profit Margin reading is -0.89%. To continue investigating profitability, this company’s Return on Assets is posted at -0.77, Equity is 1.27 and Total Capital is -0.97. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, TriSalus Life Sciences Inc’s Current Ratio is 4.08. Also, the Quick Ratio is 3.68, while the Cash Ratio stands at 2.84. Considering the valuation of this stock, the price to sales ratio is 6.79.
Transactions by insiders
Recent insider trading involved Cox Bryan F., Chief of Research, that happened on May 19 ’25 when 4764.0 shares were sold. Chief of Clinical Operations, Devlin Jodi completed a deal on May 19 ’25 to sell 4764.0 shares. Meanwhile, Chief Commercial Officer Marshak Richard sold 6597.0 shares on May 19 ’25.
